Phase II study of R–CVP followed by rituximab maintenance therapy for patients with advanced marginal zone lymphoma: consortium for improving survival of lymphoma (CISL) study

Abstract Background The response rate and survival improvement for rituximab, a CD20-targeting monoclonal antibody, have been demonstrated in marginal zone lymphoma (MZL) as monotherapy and in combination with chemotherapeutic regimens, yet relapses still occur despite treatment completion. Thus, ex...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Sung Yong Oh, Won Seog Kim, Jin Seok Kim, Seok Jin Kim, Dok Hyun Yoon, Deok-Hwan Yang, Won Sik Lee, Hyo Jung Kim, Ho-Young Yhim, Seong Hyun Jeong, Jong Ho Won, Suee Lee, Jee Hyun Kong, Sung-Nam Lim, Jun Ho Ji, Kyung A. Kwon, Gyeong-Won Lee, Jae Hoon Lee, Ho Sup Lee, Ho-Jin Shin, Cheolwon Suh
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Wiley 2019-10-01
coleção:	Cancer Communications
Assuntos:	Marginal zone Lymphoma Advanced stage Rituximab Cyclophosphamide Vincristine
Acesso em linha:	http://link.springer.com/article/10.1186/s40880-019-0403-7
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!